Liraglutide

A GLP-1 receptor agonist and one of the first FDA-approved injectable medications specifically for chronic weight management. While it requires daily dosing and produces less weight loss than newer agents, liraglutide has an extensive safety track record and remains widely used.

• Activates GLP-1 receptors to reduce appetite and caloric intake
• Slows gastric emptying for prolonged satiety
• Enhances insulin secretion in a glucose-dependent manner

• Personal or family history of medullary thyroid carcinoma
• MEN2 syndrome
• History of pancreatitis
• Pregnancy or breastfeeding

Store unused pens at 2–8°C (36–46°F). After first use, keep at room temperature (up to 30°C (86°F)) or refrigerated for up to 30 days.

The SCALE trial program demonstrated that liraglutide 3.0 mg daily produces an average weight loss of approximately 8% over 56 weeks. The LEADER cardiovascular outcomes trial showed a 13% reduction in MACE events. One of the earliest GLP-1 agents approved for weight management, with over a decade of post-marketing safety data.